Skip to main content
. 2023 Aug 22;11(8):e006944. doi: 10.1136/jitc-2023-006944

Figure 2.

Figure 2

Id-immunized mice are protected against MM cells that produce complete myeloma protein while they succumb to FLC MM cells. (A–H) BALB/c mice were immunized i.m./EP with 50 µg CCL3-scFv315 or NaCl and challenged 14 days later with MOPC315.BM.Luc.IgAλ2 cells (2×105) that produce complete M315, (left panel), (A–D) or MOPC315.BM.λ2 cells (2×105) that produce only free λ2 L chains (right panel), (E–H). (A, E) Images of whole body bioluminescence (BLI) showing mean±SEM, (B, F) representative ventral images, (C, G) serum M315 on days 0, 21 and 35 in individual mice, and (D, H) survival. End point was paraplegia. n=5–8 mice/group. Statistics: Two-way ANOVA with Bonferroni correction (A, C, E, G) and Mantel Cox Log-Rank test for survival (D, H). *p<0.05, **p<0.01, ****p<0.0001. ANOVA, analysis of variance; MM, multiple myeloma; ND, not detected; ns, not significant.